BENITIONSClinical Trial Intelligence

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Фаза 1 Идёт, набор закрыт NCT02627443

ЗаболеваниеMetastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Ovarian Endometrioid Tumor
ФазаФаза 1
СпонсорNational Cancer Institute (NCI)
СтатусИдёт, набор закрыт
Участники35 участн.
ВмешательствоBerzosertib, Carboplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
Дата начала16.05.2017
Дата завершения4.10.2024
Публикация результатов2.04.2026

Кратко

This phase I trial studies the side effects and best dose of gemcitabine hydrochloride and berzosertib when given together with carboplatin in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent) and has spread to other places in the body (metastatic). Chemotherapy drugs, such as carboplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Berzosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving berzosertib with chemotherapy (carboplatin and gemcitabine hydrochloride) may work better in treating patients with ovarian, primary peritoneal, or fallopian tube cancer compared to chemotherapy alone.

Dost Limiting Toxicity (DLT) (Phase I Dose Escalation)

Up to 28 days · Participants

Dose Level 11 Participants
Dose Level 22 Participants

Incidence of Adverse Events

Up to 3 years · Participants

Dose Level 128 Participants
Dose Level 25 Participants
Dose Level 118 Participants
Dose Level 24 Participants
Dose Level 10 Participants
Dose Level 20 Participants

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

Все исследования

Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.